Search Results

Croda International Plc and The Access to Advanced Health Institute are pleased to announce the signing of a partnership agreement around innovation and development of adjuvant formulations, under which Croda and AAHI will leverage their combined expertise to make novel vaccine adjuvant formulations globally accessible, thereby advancing next generation, robust and durable vaccines.

Croda Pharma and BSI announced that they have entered into a strategic collaboration agreement to support the sustainable sourcing of pharmaceutical grade adjuvant QS-21, a potent component of adjuvant systems.

Botanical Solution Inc. (BSI), innovator of sustainable, consistent and cost-effective Advanced Botanical Materials (ABM) for agricultural and pharmaceutical applications, has entered into a Partnership Agreement with Croda Pharma to build a robust, scalable and truly sustainable supply chain and deliver kilogram-quantities of QS-21 to the pharmaceutical industry.

Croda International Plc announces that it has entered into a cooperative agreement with the United States government in which the government will provide up to $75 million to expand the company’s U.S. manufacturing capacity of ingredients for lipid systems used in novel therapeutic drugs, such as mRNA vaccines.

◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.

Amyris, Inc. today announced that it has signed an exclusive license agreement with British specialty chemicals company Croda International Plc, or the supply of sustainable squalene.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system